Global Corona Virus (Covid-19) Market - Guidance for Executives, Management Consultants and Investment Advisors

With more than 1,26,000 cases of affected people across 114 countries, and 4,291 people losing their lives, the novel coronavirus, COVID-19 has been declared as a pandemic by World Health Organization (WHO) on 11-March-2020. As per the briefing of the Director-General of WHO, this is the first pandemic caused by a Coronavirus.

Coronaviruses are zoonotic which means that they are transmitted between animals and people. Detailed investigations of SARS-CoV found that strain was transmitted from civet cats to humans and that of MERS-CoV was transmitted from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans.

Global Corona Virus (Covid-19) Market - Guidance for Executives, Management Consultants and Investment Advisors

1 RESEARCH METHODOLOGY

 

1.1 DESK RESEARCH

1.1.1 PRELIMINARY ANALYSIS

1.1.2 PAID DATABASES AND GOVERNMENT BODIES

1.1.3 APPLICATION SEGMENT ANALYSIS

1.1.3.1 TOP DOWN APPROACH

1.1.3.2 BOTTOM UP APPROACH

 

1.2 PRIMARY RESEARCH

 

1.2.1 BREAKDOWN OF PRIMARY INTERVIEW

1.2.2 DISCUSSION GUIDE WITH PRIMARY PARTICIPANTS

1.3 ANALYSIS AND OUTPUT

1.3.1 COUNTRY/REGIONAL ANALYSIS

1.3.2 PREDICTIVE ANALYTICS TECHNIQUES

1.3.3 INHOUSE AI POWERED REAL TIME ANALYSIS TOOL

1.4 FINAL OUTPUT FROM DESK AND PRIMARY RESEARCH

1.5 ASSUMPTIONS AND LIMITATIONS

1.5.1 RESEARCH ASSUMPTIONS

1.5.2 RESEARCH LIMITATIONS

 

2 ECOSYSTEM OVERVIEW

 

3. INTRODUCTION AND MARKET DEFINITION

 

3.1 WHAT ARE PANDEMICS? 

3.2 THE ROLE OF ZOONOSIS

3.3 MARKET DEFINITION

3.3.1 REVENUE MARKET SIZE

3.3.2 GROSS DOMESTIC PRODUCT

3.3.3 TOURISM-HOTELS

3.3.4 TOURISM-GROUND 

3.3.5 TOURISM-AIR

3.3.6 TOURISM-CRUISE

3.3.7 TOURISM-OTHER

3.3.8 MEDICAL -THERAPEUTIC

3.3.9 MEDICAL -DIAGNOSTIC

3.3.10 MEDICAL -PPE

3.4 METHODOLOGY 

3.4.1 AUTHORS

3.4.2 SOURCES

3.5 HISTORICAL PERSPECTIVE ON PANDEMICS

3.5.1 HIV/AIDS PANDEMIC 2005-2012

3.5.2 FLU PANDEMIC 1968

3.5.3 ASIAN FLU 1956-1958

3.5.4 SPANISH FLU 1918

3.5.5 SIXTH CHOLERA PANDEMIC 1910-1911

3.5.6 FLU PANDEMIC 1889-1890

3.5.7 THE BLACK DEATH 1346-1353

 

4. THE PANDEMIC OVERVIEW

 

4.1 WHAT IS A VIRUS? 

4.1.1 IS A VIRUS ALIVE?

4.1.2 VIRAL STRUCTURE

4.1.3 THE VIRAL GENOME

4.1.4 VIRAL MUTATION

4.2 THE CORONAVIRUS

4.2.1 SEVERE ACUTE RESPIRATORY SYNDROME (SARS)

4.2.2 MIDDLE EAST RESPIRATORY SYNDROME (MERS)

4.2.3 CORONAVIRUS DISEASE 2019 (COVID-19)

4.2.3.1 SIGNS AND SYMPTOMS

4.2.3.2 CAUSE

4.2.3.3 DIAGNOSIS

4.2.3.4 PREVENTION

4.2.3.5 MANAGEMENT

4.2.3.6 PROGNOSIS

4.2.3.7 EPIDEMIOLOGY

4.2.3.8 MISINFORMATION ABOUT THE OUTBREAK

4.3 PANDEMIC DIAGNOSTICS

4.3.1 RISK MANAGEMENT–SPARK AND SPREAD

4.3.2 DX TECHNOLOGY–GENOMIC AND WGS ROLE

4.3.3 DX TECHNOLOGY- IMMUNOASSAY

4.3.4 DX TECHNOLOGY-OTHER

4.3.5 TIME TO MARKET AND PREPAREDNESS ISSUES

4.4 THERAPEUTICS

4.4.1 VACCINE

4.4.2 DUAL ROLE OF VACCINES

4.4.3 ANTIVIRAL

 

5. COVID-19 SCENARIOS

 

5.1 SCENARIOS OVERVIEW

5.2 SCENARIO 1. LIMITED SPREAD & EARLY VACCINE

5.3 SCENARIO 2. CONTAINED SPREAD & MIDTERM VACCINE

5.4 SCENARIO 3. UNCONTAINED SPREAD & LATE VACCINE

 

6. RECENT DEVELOPMENTS

 

6.1 RECENT DEVELOPMENTS– IMPORTANCE AND HOW TO USE THIS SECTION

6.1.1 IMPORTANCE OF THESE DEVELOPMENTS

6.1.2 HOW TO USE THIS SECTION

6.1.2.1 GENEREX SIGNS CONTRACT TO DEVELOP A COVID-19 VACCINE

6.1.2.2 APPLIED DNA, TAKIS BIOTECH PARTNER TO DESIGN COVID-19 VACCINES

6.1.2.3 CODAGENIX DEVELOPING A CORONAVIRUS VACCINE

6.1.2.4 BREAKTHROUGH FROM MIGAL RESEARCH INSTITUTE IN DEVELOPMENT OF COVID-19 VACCINE

6.1.2.5 NOVAVAX ADVANCES DEVELOPMENT OF NOVEL COVID-19 VACCINE

6.1.2.6 COVID-19 CAUSES AIR TRAVEL TO FALL FOR FIRST TIME IN 11 YEARS

6.1.2.7 STEEP DROP IN CHINESE AIR TRAVEL DEMAND

6.1.2.8 NEW TECH COULD MAKE CORONAVIRUS VACCINE IN RECORD TIME

6.1.2.9 VAXART ANNOUNCES INITIATION OF CORONAVIRUS VACCINE PROGRAM

6.1.2.10 CORONAVIRUS DETECTION TEST DEVELOPMENT BY CO-DIAGNOSTICS

6.1.2.11 GEOVAX, BRAVOVAX TO DEVELOP VACCINE FOR CORONAVIRUS

6.1.2.12 DIAGNOSING CORONAVIRUS IN THE LAB

6.1.2.13 VEREDUS LAB DEVELOPS TEST FOR CORONAVIRUS DETECTION

6.1.2.14 U.S. PORK PRODUCERS FEAR PANDEMIC

6.1.2.15 FIRST NEW HIV STRAIN IN19 YEARS IDENTIFIED

6.1.2.16 FLU-LIKE EPIDEMIC COULD KILL 80 MN GLOBALLY

6.1.2.17 NIPAH VIRUS A GLOBAL THREAT

6.1.2.18 NEW DRC EBOLA CASES CONFIRMED AS FDA OKS RAPID TEST

6.1.2.19 ONTERA AWARDED CONTRACT FOR ZIKA GENOTYPING TEST

6.1.2.20 TWO NEWMEMBERS JOIN GLOBAL DIAGNOSTICS NETWORK

6.1.2.21 BARDA FUNDING HEALTH SECURITY SOLUTIONS

 

7. COVID-19 ECONOMIC IMPACT ON GROSS DOMESTIC PRODUCT

 

7.1 ECONOMIC IMPACT OVERVIEW BY COUNTRY

7.1.1 TABLE–ECONOMIC IMPACT BY COUNTRY SCENARIO 1

7.1.2 CHART–ECONOMIC IMPACT BY COUNTRY SCENARIO 1

7.1.3 TABLE–ECONOMIC IMPACT BY COUNTRY SCENARIO 2

7.1.4 CHART–ECONOMIC IMPACT BY COUNTRY SCENARIO 2

7.1.5TABLE–ECONOMIC IMPACT BY COUNTRY SCENARIO 3

7.1.6 CHART–ECONOMIC IMPACT BY COUNTRY SCENARIO 3

7.2 TOURISM GLOBAL MARKET BY SEGMENT-OVERVIEW

7.2.1 TABLE–TOURISM GLOBAL MARKET BY SEGMENT AND SCENARIO

7.2.2 CHART–TOURISM GLOBAL MARKET BY SEGMENT AND SCENARIO–2019/2024 COMPARISON

7.2.3 CHART–TOURISM GLOBAL MARKET BY SEGMENT AND SCENARIO–2019

7.2.4 CHART–TOURISM GLOBAL MARKET BY SEGMENT AND SCENARIO–2024

7.2.5 CHART–TOURISM GLOBAL MARKET BY SEGMENT AND SCENARIO–SHARE BY YEAR

7.3 MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO-OVERVIEW

7.3.1 TABLE–MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO

7.3.2 CHART–MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO–2019/2024 COMPARISON

7.3.3 CHART–MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO–2019

7.3.4 CHART–MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO–2024

7.3.5 CHART–MEDICAL GLOBAL MARKET BY SEGMENT AND SCENARIO–SHARE BY YEAR

 

8. TOURISM GLOBAL MARKETS–BY SEGMENT AND SCENARIO

 

8.1 HOTELS

8.1.1 TABLE HOTEL MARKET BY SCENARIO AND BY COUNTRY

8.1.2 CHART-HOTEL MARKET GROWTH BY SCENARIO

8.2 GROUND

 8.2.1 TABLE GROUND MARKET BY SCENARIO AND BY COUNTRY

8.2.2 CHART-GROUND MARKET GROWTH BY SCENARIO

8.3 AIR TRAVEL

8.3.1 TABLE AIR TRAVEL BY SCENARIO AND BY COUNTRY

8.3.2 CHART–AIR TRAVEL GROWTH BY SCENARIO

8.4 CRUISE MARKET

8.4.1 TABLE CRUISE MARKET BY SCENARIO AND BY COUNTRY

8.4.2 CHART-CRUISE MARKET GROWTH BY SCENARIO

8.5 OTHER TOURISM

8.5.1 TABLE OTHER TOURISM BY SCENARIO AND BY COUNTRY

8.5.2 CHART-OTHER TOURISM GROWTH BY SCENARIO

 

9. MEDICAL GLOBAL MARKETS–BY SEGMENT AND SCENARIO

 

9.1 THERAPEUTIC

9.1.1 TABLE THERAPEUTIC MARKETS BY SCENARIO AND BY COUNTRY

9.1.2 CHART-THERAPEUTIC MARKETS GROWTH BY SCENARIO

9.2 DIAGNOSTICS

9.2.1 TABLE DIAGNOSTICS MARKET GROWTH BY SCENARIO AND BY COUNTRY

9.2.2 CHART-DIAGNOSTICS MARKET GROWTH BY SCENARIO

9.3 PPE

9.3.1 TABLE PPE MARKET BY SCENARIO AND BY COUNTRY

9.3.2 CHART-PPE MARKET GROWTH BY SCENARIO

 

10 COMPANY PROFILE

 

10.1 APPLIED DNA SCIENCES, INC

10.2 CODAGENIX

10.3 GEOVAX LABS, INC

10.4 TAKIS BIOTECH

10.5 EVVIVAX

10.6 ZYDUS CADILA

10.7 MIGAL GALILEE RESEARCH INSTITUTE

10.8 GENEREX BIOTECHNOLOGY CORPORATION

10.9 MODERNA THERAPEUTICS

10.10 NOVAVAX

10.11 BRAVOVAX

10.12 ASCLETIS PHARMA

10.13 JANSSEN PHARMACEUTICALS

10.14 ALTIMMUNE

10.15 OTHER COMPANIES